Cite
HARVARD Citation
Yuan, X. et al. (2022). Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan‐L‐CN randomized controlled trial. Diabetes, obesity & metabolism. 24 (11), pp. 2182-2191. [Online].